{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:51:47Z","timestamp":1793242307741,"version":"4.5.0"},"reference-count":118,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T00:00:00Z","timestamp":1738454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425050"],"award-info":[{"award-number":["82425050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2024-1-4074"],"award-info":[{"award-number":["2024-1-4074"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Z211100002921069"],"award-info":[{"award-number":["Z211100002921069"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["82425050"],"award-info":[{"award-number":["82425050"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2024-1-4074"],"award-info":[{"award-number":["2024-1-4074"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["Z211100002921069"],"award-info":[{"award-number":["Z211100002921069"]}]},{"name":"Capital Clinical Diagnosis and Treatment Technology Research and Transformation Application Program of China","award":["82425050"],"award-info":[{"award-number":["82425050"]}]},{"name":"Capital Clinical Diagnosis and Treatment Technology Research and Transformation Application Program of China","award":["2024-1-4074"],"award-info":[{"award-number":["2024-1-4074"]}]},{"name":"Capital Clinical Diagnosis and Treatment Technology Research and Transformation Application Program of China","award":["Z211100002921069"],"award-info":[{"award-number":["Z211100002921069"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>CD30 is overexpressed in many T-cell lymphoma (TCL) entities, including subsets of peripheral T-cell lymphomas (PTCL) and cutaneous T-cell lymphomas (CTCL). The antibody\u2013drug conjugate brentuximab vedotin (BV), targeting CD30-positive cells, has been approved for the treatment of relapsed or refractory (R\/R) systemic anaplastic large cell lymphoma (sALCL), and primary cutaneous anaplastic large cell lymphoma or mycosis fungoides in patients who have received previous systemic therapy. However, many patients still experience disease progression after BV monotherapy. Extensive efforts have been dedicated to investigating effective combinations of BV. A phase III clinical study demonstrated that the combination of BV with cyclophosphamide, doxorubicin, and prednisone (CHP) is superior to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for CD30-positive PTCL. This study led to the approval of BV with CHP as the first-line therapy for CD30-positive PTCL (sALCL in Europe). We summarize the encouraging combination applications of BV in this review. Ongoing studies on combination therapies of BV are also listed, highlighting potential directions for the future application of BV. We focus on dissecting the underlying mechanisms of BV, discussing its effects on both tumor cells and the tumor microenvironment. Exploring resistance mechanisms in TCL provide valuable insights for optimizing BV-based therapies in the future.<\/jats:p>","DOI":"10.3390\/cancers17030496","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T09:35:07Z","timestamp":1738575307000},"page":"496","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Antibody\u2013Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3531-0637","authenticated-orcid":false,"given":"Yi","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Peking University First Hospital, Beijing 100034, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China"},{"name":"NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Peking University First Hospital, Beijing 100034, China"},{"name":"The Second Clinical Medical School, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7805-2861","authenticated-orcid":false,"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Peking University First Hospital, Beijing 100034, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China"},{"name":"NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing 100034, China"},{"name":"Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,2]]},"reference":[{"key":"ref_1","unstructured":"National Comprehensive Cancer Network (2025, January 22). (NCCN) Clinical Practice Guidelines in Oncology. T-Cell Lymphomas (Version 1.2025). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s11912-022-01310-3","article-title":"Management of Peripheral T-cell Lymphomas and the Role of Transplant","volume":"24","author":"Foley","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12943-023-01904-w","article-title":"Therapeutic challenges in peripheral T-cell lymphoma","volume":"23","author":"Luan","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamadermatol.2023.2634","article-title":"Prognostic Factors and Survival Outcomes Among Patients With Mycosis Fungoides in China: A 12-Year Review","volume":"159","author":"Chen","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: Validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/bjd.20786","article-title":"Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: A single-centre retrospective review","volume":"186","author":"Davison","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/jdv.18563","article-title":"Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry","volume":"37","author":"Muniesa","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Chen, X., Wu, W., Wei, W., and Zou, L. (2022). Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.869488"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cbpa.2010.06.170","article-title":"Antibody-drug conjugates: Targeted drug delivery for cancer","volume":"14","author":"Alley","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood-2014-06-537514","article-title":"Brentuximab vedotin","volume":"124","author":"Ansell","year":"2014","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"Martin","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1007\/s00277-020-04204-1","article-title":"Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma","volume":"99","author":"Piukovics","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_20","unstructured":"(2025, January 25). European Commission Approves ADCETRIS\u00ae (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD. Available online: https:\/\/www.takedaoncology.com\/news\/news-releases\/European-Commission-Approves-ADCETRIS-brentuximab-vedotin-for-the-Treatment-of-Adult-Patients-with-Previously-Untreated-CD30+-Stage-III-Hodgkin-Lymphoma-in-Combination-with-AVD\/."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9397","DOI":"10.1182\/blood-2022-158681","article-title":"Tub-010, a Novel Antibody-Drug-Conjugate with Reduced Nonspecific Toxicity Profile Based on Tub-Tag Technology Widens the Therapeutic Window for the Treatment of CD30+ Malignancies","volume":"140","author":"Gerlach","year":"2022","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1674.1671","DOI":"10.1182\/blood-2024-194011","article-title":"Trial in Progress: Open-Label Phase 1 Study to Evaluate Safety of SGN-35C in Adults with Select Relapsed\/Refractory Lymphomas (SGN35C-001)","volume":"144","author":"Herrera","year":"2024","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/blood-2023-182400","article-title":"SGN-35C: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas","volume":"142","author":"Hamblett","year":"2023","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/bjh.15742","article-title":"A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks","volume":"186","author":"Poston","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e23365","DOI":"10.1096\/fj.202301747RR","article-title":"CD30 plays a role in T-dependent immune response and T cell proliferation","volume":"38","author":"Cui","year":"2024","journal-title":"Faseb J"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00062752-200307000-00003","article-title":"Expression and a role of CD30 in regulation of T-cell activity","volume":"10","author":"Tarkowski","year":"2003","journal-title":"Curr. Opin. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions","volume":"7","author":"Pileri","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00277-022-05054-9","article-title":"Anti-CD30 antibody-drug conjugate therapy in lymphoma: Current knowledge, remaining controversies, and future perspectives","volume":"102","author":"Prince","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: High correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Nakashima, M., and Uchimaru, K. (2023). CD30 Expression and Its Functions during the Disease Progression of Adult T-Cell Leukemia\/Lymphoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108731"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41408-022-00644-2","article-title":"Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication","volume":"12","author":"Huo","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and S\u00e9zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/ajcp\/aqaa261","article-title":"Prognostic Significance of CD30 in Transformed Mycosis Fungoides","volume":"156","author":"Travaglino","year":"2021","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_35","first-page":"532","article-title":"Evaluation of mortality, prognostic parameters, and treatment efficacy in mycosis fungoides","volume":"22","author":"Porkert","year":"2024","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1182\/blood-2002-11-3507","article-title":"MEK\/ERK pathway is aberrantly active in Hodgkin disease: A signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival","volume":"102","author":"Zheng","year":"2003","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Li, Z., Guo, W., and Bai, O. (2023). Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1301437"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"216616","DOI":"10.1016\/j.canlet.2024.216616","article-title":"CD30 protects EBV-positive diffuse large B-cell lymphoma cells against mitochondrial dysfunction through BNIP3-mediated mitophagy","volume":"583","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/asj\/sjac234","article-title":"CD30 Regulation of IL-13-STAT6 Pathway in Breast Implant-Associated Anaplastic Large Cell Lymphoma","volume":"43","author":"Kadin","year":"2023","journal-title":"Aesthet. Surg. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jaad.2014.10.006","article-title":"Cutaneous manifestations of human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia\/lymphoma: A single-center, retrospective study","volume":"72","author":"Marchetti","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1200\/jco.2015.33.15_suppl.8552","article-title":"CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project","volume":"33","author":"Federico","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/hon.2482","article-title":"Frequent expression of CD30 in extranodal NK\/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy","volume":"36","author":"Kawamoto","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3892\/ol.2017.5592","article-title":"Prognostic significance of CD30 expression in nasal natural killer\/T-cell lymphoma","volume":"13","author":"Wang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjd.13832","article-title":"Histopathological and immunophenotypical criteria for the diagnosis of S\u00e9zary syndrome in differentiation from other erythrodermic skin diseases: A European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases","volume":"173","author":"Klemke","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","article-title":"Prognostic factors in transformed mycosis fungoides: A retrospective analysis of 100 cases","volume":"119","author":"Benner","year":"2012","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clml.2015.11.010","article-title":"Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides","volume":"16","author":"Talpur","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.hoc.2016.11.006","article-title":"CD30(+) Lymphoproliferative Disorders of the Skin","volume":"31","author":"Sauder","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2141.2008.07146.x","article-title":"Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma","volume":"142","author":"Oflazoglu","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","article-title":"Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate","volume":"16","author":"Okeley","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1021\/bc050201y","article-title":"Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides","volume":"16","author":"Sun","year":"2005","journal-title":"Bioconjug Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and S\u00e9zary Syndrome with Variable CD30 Expression Level: A Multi-Institution Collaborative Project","volume":"33","author":"Kim","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1200\/JCO.2024.42.16_suppl.7069","article-title":"Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study","volume":"42","author":"Iyer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1016\/S2352-3026(24)00171-6","article-title":"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 study","volume":"11","author":"Herrera","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/bjd\/ljac012","article-title":"Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma","volume":"188","author":"Oymanns","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1182\/blood-2023-178279","article-title":"Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin","volume":"142","author":"Poh","year":"2023","journal-title":"Blood"},{"key":"ref_63","first-page":"383","article-title":"Combination of brentuximab-vedotin with skin-directed therapies extends the time to the next therapeutic line in patients with cutaneous T-cell lymphoma","volume":"19","author":"Stranzenbach","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00280-023-04609-5","article-title":"The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis","volume":"93","author":"Tonozuka","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41375-024-02441-1","article-title":"Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma","volume":"39","author":"Suto","year":"2024","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: Results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-139224","article-title":"Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. \u201cthe TOTAL Trial\u201d","volume":"136","author":"Tournilhac","year":"2020","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood-2021-153709","article-title":"The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab Vedotin and CHP Followed By Consolidation with High-Dose Therapy\u2014Autologous Stem-Cell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma","volume":"138","author":"Sibon","year":"2021","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1182\/blood-2022-157201","article-title":"A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-Cell Lymphoma","volume":"140","author":"Barta","year":"2022","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1182\/blood-2023-181397","article-title":"Brentuximab Vedotin in Combination with Methotrexate, L-Asparaginase, and Dexamethasone (B-MAD) As Frontline Treatment for Patients with Extranodal NK\/T-Cell Lymphoma","volume":"142","author":"Bunworasate","year":"2023","journal-title":"Blood"},{"key":"ref_73","first-page":"634","article-title":"ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin","volume":"57","author":"Arai","year":"2016","journal-title":"Rinsho Ketsueki"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1182\/blood-2007-06-097014","article-title":"Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30","volume":"110","author":"Oflazoglu","year":"2007","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Cho, H., Shim, M.K., Moon, Y., Song, S., Kim, J., Choi, J., Kim, J., Lee, Y., Park, J.Y., and Kim, Y. (2022). Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14102131"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jcmm.13344","article-title":"Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines","volume":"22","author":"Nettersheim","year":"2018","journal-title":"J. Cell Mol. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10928-016-9495-8","article-title":"Quantitative characterization of in vitro bystander effect of antibody-drug conjugates","volume":"43","author":"Singh","year":"2016","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"Oncologist"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1080\/10428194.2016.1256481","article-title":"Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry","volume":"58","author":"Bartlett","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Lobastova, L., Lettau, M., Babatz, F., de Oliveira, T.D., Nguyen, P.H., Pauletti, B.A., Schauss, A.C., D\u00fcrkop, H., Janssen, O., and Paes Leme, A.F. (2021). CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.698503"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"30523","DOI":"10.18632\/oncotarget.8864","article-title":"CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro","volume":"7","author":"Hansen","year":"2016","journal-title":"Oncotarget"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ccell.2020.11.009","article-title":"Immunomodulation by targeted anticancer agents","volume":"39","author":"Petroni","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.oraloncology.2019.06.016","article-title":"Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer","volume":"95","author":"Park","year":"2019","journal-title":"Oral Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/imr.13301","article-title":"Decoding immunogenic cell death from a dendritic cell perspective","volume":"321","author":"Janssens","year":"2024","journal-title":"Immunol. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1016\/j.celrep.2019.08.057","article-title":"GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses","volume":"28","author":"Kashyap","year":"2019","journal-title":"Cell Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: Phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1517\/13543780802493440","article-title":"SGN-30: A basis for the effective treatment of CD30 positive hematopoietic malignancies","volume":"17","year":"2008","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_95","first-page":"3736","article-title":"The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease","volume":"62","author":"Wahl","year":"2002","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/sj.leu.2403884","article-title":"Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics","volume":"19","author":"Cerveny","year":"2005","journal-title":"Leukemia"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1349-7006.2009.01354.x","article-title":"Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo","volume":"101","author":"Maeda","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","article-title":"A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies","volume":"111","author":"Bartlett","year":"2008","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Leonard","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-09-0162","article-title":"A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders","volume":"15","author":"Duvic","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/cup.13545","article-title":"Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin","volume":"46","author":"Goyal","year":"2019","journal-title":"J. Cutan. Pathol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/cup.12797","article-title":"Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: A novel finding","volume":"43","author":"Patel","year":"2016","journal-title":"J. Cutan. Pathol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","article-title":"Resistance to Antibody-Drug Conjugates","volume":"78","author":"Pandiella","year":"2018","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Abelman, R.O., Wu, B., Spring, L.M., Ellisen, L.W., and Bardia, A. (2023). Mechanisms of Resistance to Antibody-Drug Conjugates. Cancers, 15.","DOI":"10.3390\/cancers15041278"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"101086","DOI":"10.1016\/j.drup.2024.101086","article-title":"Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement","volume":"75","author":"Jiang","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00428-024-03764-1","article-title":"Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy","volume":"484","author":"Kaimi","year":"2024","journal-title":"Virchows Arch."},{"key":"ref_109","first-page":"894","article-title":"Loss of CD30 Expression in Anaplastic Large Cell Lymphoma Following Brentuximab Therapy","volume":"15","author":"Nielson","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","article-title":"CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin","volume":"14","author":"Chen","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Hansen, H.P., Paes Leme, A.F., and Hallek, M. (2020). Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00398"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/1538-7445.AM2014-688","article-title":"Abstract 688: Characterization and circumvention of drug resistance mechanisms in SGN-35-resistant HL and ALCL clonal cell lines","volume":"74","author":"Lewis","year":"2014","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e1421889","DOI":"10.1080\/2162402X.2017.1421889","article-title":"Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells","volume":"7","author":"Tosetti","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3324\/haematol.2021.278469","article-title":"Inhibitors of ADAM10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect","volume":"107","author":"Pece","year":"2022","journal-title":"Haematologica"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/vco.12260","article-title":"IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells","volume":"15","author":"Bauer","year":"2017","journal-title":"Vet. Comp. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Liu-Kreyche, P., Shen, H., Marino, A.M., Iyer, R.A., Humphreys, W.G., and Lai, Y. (2019). Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00749"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1158\/1078-0432.CCR-19-1768","article-title":"Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma","volume":"26","author":"Chen","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1158\/1078-0432.CCR-19-4137","article-title":"A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models","volume":"26","author":"Wei","year":"2020","journal-title":"Clin. Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/496\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:25:45Z","timestamp":1760027145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,2]]},"references-count":118,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cancers17030496"],"URL":"https:\/\/doi.org\/10.3390\/cancers17030496","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,2]]}}}